Human macrophages engineered to secrete a bispecific T cell engager support antigen-dependent T cell responses to glioblastoma

BACKGROUND: Targeted and effective treatment options are needed for solid tumors, including glioblastoma (GBM), where survival rates with standard treatments are typically less than 2 years from diagnosis. Solid tumors pose many barriers to immunotherapies, including therapy half-life and persistenc...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:J Immunother Cancer
Main Authors: Gardell, Jennifer L, Matsumoto, Lisa R, Chinn, Harrison, DeGolier, Kole R, Kreuser, Shannon A, Prieskorn, Brooke, Balcaitis, Stephanie, Davis, Amira, Ellenbogen, Richard G, Crane, Courtney A
Formato: Artigo
Idioma:Inglês
Publicado: BMJ Publishing Group 2020
Assuntos:
Immune Cell Therapies and Immune Cell Engineering
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7597484/
https://ncbi.nlm.nih.gov/pubmed/33122397
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2020-001202
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares